Covalent binder design with Gen AI & FBDD
Covalent small molecule drugs are highly valued for their ability to precisely inhibit challenging “hard-to-drug” proteins by forming stable, irreversible bonds with […]
De Novo PROTAC Design with Gen AI and FBDD
A PROTAC (PROteolysis TArgeting Chimera) is a small molecule that facilitates the degradation of disease-causing proteins by recruiting an E3 ubiquitin ligase […]
Long-Read Sequencing (with ONT) proves useful in Biosynthesis Troubleshooting
This blog post will expand on the use of long-read sequencing (LRS) with Oxford Nanopore Technologies (ONT) for addressing genome truncation challenges […]
Large Language Models for Chart Review Automation in Medical Affairs
The Evolution of Chart Reviews: From NLP to LLMs Traditionally, chart reviews have been labor-intensive, requiring meticulous manual extraction of relevant information […]
Understanding Drug Selectivity: A Computational Perspective
Importance of Drug Selectivity Drug selectivity refers to the ability of a drug to preferentially interact with a specific target, such as […]
Making AI your Research Collaborator: Examples from Biopharma
It’s been 18+ months since OpenAI released ChatGPT. Generative AI is revolutionizing productivity in many professions. Programmers are benefitting from Large Language […]
Importance of permeability prediction for structure-based in silico drug design of novel anti-tuberculosis leads
Mycobacterium tuberculosis (M. tb), the causative agent of tuberculosis (TB), exhibits a concerning propensity to develop drug resistance. This necessitates the discovery […]
Accelerating antibody & nanobody design for research use cases with Generative AI
Role of Antibodies in research Antibodies are foundational tools in research and diagnostics in addition to being the largest biological modality in […]
Target elucidation: Key first steps for structure based in silico drug design
BioPharma wins come after long and hard fought battles. Every phase of a drug discovery battle poses its own challenges. Deep Science and Deep Tech innovations are continuously expanding the options available for addressing these challenges.
Industry-Academia collaborations to design next generation anti-malaria drugs
Partnership between academic research institutions and the biopharma industry has been essential for making breakthrough discoveries in disease research and translating those discoveries into therapies available in the clinic.
Rare Disease Day, 2024
Rare diseases affect a staggering 300 million people worldwide. Often genetic in origin, rare diseases demand our attention and support for research. On Rare Disease Day, we highlight the challenges faced by these individuals and the urgent need for solutions.
AI Everywhere
A lot changed in 2023. The widespread use of AI through ChatGPT changed perceptions of the use and relevance of AI in creative tasks.Beyond its ability to seemingly understand questions and generate responses in natural language, we at Aganitha see an opportunity to make AI understand and speak the language of life - DNA, RNA, protein sequences, molecules, genes, targets, drugs, and so on.